Thyroid Ultrasound, Fine-Needle Aspiration Linked to Thyroid Cancer Incidence
the Cancer Therapy Advisor take:
An increased incidence of thyroid cancer may be the result of increased use of thyroid ultrasound and fine-needle aspiration (FNA), according to a Veterans Affairs (VA) study published in Cancer.
Jose Zevallos, MD, MPH, FACS, and colleagues at the University of North Carolina at Chapel Hill examined VA administrative data from 2000 to 2012, hypothesizing that incidence of thyroid cancer would correspond to increases in ultrasound and FNA modalities.
The researchers found a jump in thyroid cancer incidence per 100,000 individuals, from 10.3 in 2000 to 21.5 in 2012. At the same time, rate of thyroid ultrasound use jumped from 125.6 in 2001 to 572.1 in 2012, while FNA went from 7 in 200 to 46 in 2012.
There was a statistically significant increase in thyroid cancer incidence from 2000 to 2008, followed by more pronounced increase from 2008 to 2012, which corresponded with an increase in thyroid ultrasound use from 2002 to 2012 and FNA from 2000 to 2012.
“These findings suggest that the increase in thyroid cancer incidence may be related to increases in the use of thyroid ultrasound and FNA,” the authors concluded.
An increased incidence of thyroid cancer may be the result of increased use of thyroid ultrasound and fine-needle aspiration.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
- Opinion: Understanding the FDA's Take on Cannabidiol
- High IDO1 Tumor Expression May Predict Poor Overall Survival in Patients With Anal Cancer
- Ambient Benzene Exposure and Risk of Hematologic Malignancies
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma